New York—The use of remifentanil in patients undergoing flexible bronchoscopy resulted in no change in the length of stay in the PACU, despite worse ASA status and greater case complexity, according to a new study. The researchers also found that PACU length of stay was unchanged in rigid bronchoscopy patients who received remifentanil, despite a nearly 50% increase in duration of the operation.
“This project began in 2013, when remifentanil began to first be utilized for this type